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Summary and Conclusions
ͻ Amikacin guidelines for mycobacterial infections achieve peak concentrations that are typically within or above the stated target range.
ͻ Trough concentrations are excessive for patients with renal impairment (CrCl <30 mL/min).
ͻ Guidelines should be modified to allow greater flexibility in peak concentrations and to provide guidance for patients with renal impairment.
Aim
ͻ To determine whether amikacin dosage guidelines for multi-drug resistant 
mycobacterial infections achieve peaks of 35-45 mg/L (OD) or 65-80 mg/L 
(TW) and troughs <5 mg/L.
Tamara M Cairney1,2, Bao Lock2, Fiona Robb1, Alison H Thomson1,2
1NHS Greater Glasgow and Clyde, Glasgow, 2University of Strathclyde, Glasgow
Introduction
ͻ Amikacin is increasingly being used in the management of multi-drug resistant 
mycobacterial infection.
ͻ Current dosing guidelines recommend 15 mg/kg once daily (OD) or 25 mg/kg 
thrice weekly (TW).1
ͻ Target concentrations for amikacin are end of infusion peaks of 35-45 mg/L 
(OD) or 65-80 mg/L (TW) and troughs <5 mg/L.1
ͻ It is not clear whether the recommended amikacin dosage guidelines achieve 
these target concentrations.
Results
ͻ Data were collected from 83 patients (Table 1), of which 33% (OD) and 35% (TW) had predicted peaks within the relevant target amikacin range (Table 2).
ͻ Concentrations were more likely to be above than below the upper concentration target range (Table 2, Figure 1 and Figure 2).
ͻ 34% of patients achieved peaks >50 mg/L with the OD regimen and 11% of patients achieved peaks of >100 mg/L on the TW regimen.
ͻ Patients with estimated creatinine clearance <30 mL/min had troughs >5 mg/L at the end of the dosage interval.
Amikacin Concentrations and Target 
Ranges for Mycobacterial Infection
Methods
ͻ Patients >18 years old with a mycobacterial infection and at least one 
recorded amikacin dose and peak concentration were included in the audit.
ͻ The following data were extracted from drug monitoring forms: age; weight; 
height; creatinine concentration; amikacin doses, concentrations and times.
ͻ Individual estimates of amikacin volume of distribution (V) and clearance (CL) 
were determined by MAP Bayesian pharmacokinetic analysis.2
ͻ Individual CL and V estimates were used to predict the following amikacin 
concentrations 
ʹ 15 mg/kg daily 1 h and 24 h after the start of a 1 h infusion
ʹ 25 mg/kg thrice weekly 1 h and 48 h after the start of a 1 h infusion 
ͻ The percentages of patients who achieve amikacin concentrations below, 
within and above the target peak and trough ranges were determined for 
each regimen.
Clinical characteristics Number/Median (Range)
Patients (Male/Female) 83 (49/34)
Age 45 (19 ʹ 79)
Weight 60 (36 ʹ 94)
Estimated Creatinine Clearance (mL/min) 69 (60 ʹ 193)
Estimated Amikacin Clearance (L/h) 4.0 (0.49 ʹ 10.4)
Estimated Amikacin Volume of Distribution (L) 17.9 (8.6 ʹ 44.4)
Figure 1 Predicted steady state peak and trough amikacin  concentrations 
ONCE DAILY regimen 
Figure 2 Predicted steady state peak and trough amikacin concentrations   
THRICE WEEKLY regimen
Regimen Amikacin Concentration 
(mg/L)
Percentage 
of Patients
15 mg/kg 
once daily
Peak <35 14%
Peak 35 ʹ 45 33%
Peak >45 53%
Trough <5 94%
25 mg/kg 
thrice weekly
Peak <65 25%
Peak 65 ʹ 80 35%
Peak >80 40%
Trough <5 95%
Table 1 Patient demographic and clinical data Table 2 Percentages of amikacin peaks and troughs within ranges 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
0 20 40 60 80
A
m
ik
a
c
in
C
o
n
c
e
n
tr
a
ti
o
n
 (
m
g
/
L
)
Patient Number
Peak Concentration
Trough Concentration
Target Range Limits
Trough Limit
0.0
20.0
40.0
60.0
80.0
100.0
120.0
0 20 40 60 80
A
m
ik
a
c
in
 C
o
n
c
e
n
tr
a
ti
o
n
 (
m
g
/
L
)
Patient Number
Peak Concentration
Trough Concentration
Target Range Limits
Trough Limit
